Documents
Application Sponsors
NDA 215446 | MITSUBISHI TANABE | |
Marketing Status
Application Products
001 | SOLUTION;INTRAVENOUS | 105MG/5ML | 0 | RADICAVA ORS | EDARAVONE |
FDA Submissions
TYPE 3; Type 3 - New Dosage Form | ORIG | 1 | AP | 2022-05-12 | PRIORITY |
Submissions Property Types
TE Codes
CDER Filings
MITSUBISHI TANABE
cder:Array
(
[0] => Array
(
[ApplNo] => 215446
[companyName] => MITSUBISHI TANABE
[docInserts] => ["",""]
[products] => [{"drugName":"RADICAVA ORS","activeIngredients":"EDARAVONE","strength":"105MG\/5ML","dosageForm":"SOLUTION;INTRAVENOUS","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
[labels] => [{"actionDate":"05\/12\/2022","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2022\\\/215446s000lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"05\/12\/2022","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 3 - New Dosage Form","reviewPriority":"PRIORITY; Orphan","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2022\\\/215446s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2022\\\/215446Orig1s000ltr.pdf\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2022-05-12
)
)